Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
October 29 2020 - 6:06AM
Edgar (US Regulatory)
Free
Writing Prospectus dated October 28, 2020
Filed
Pursuant to Rule 433
Relating
to the Preliminary Prospectus Supplement dated October 28, 2020
Registration
No. 333-239497
Cancer
Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million
Rutherford,
N.J. — October 28, 2020 – Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug
discovery and preclinical oncology and immuno-oncology services, announced today that, due to demand, the underwriter has agreed
to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,363,637 shares of common
stock of the Company at a price to the public of $2.20 per share, less underwriting discounts and commissions. The offering is
expected to close on or about November 2, 2020, subject to satisfaction of customary closing conditions.
H.C.
Wainwright & Co. is acting as the sole book-running manager for the offering.
The
Company has also granted to the underwriter a 30-day option to purchase up to an additional 204,545 shares of common stock at
the public offering price, less underwriting discounts and commissions. The gross proceeds of the offering are expected to be
approximately $3.0 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding the
underwriter’s option to purchase additional shares. Cancer Genetics intends to use the net proceeds to fund working capital
and other general corporate purposes.
A
shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed
with the Securities and Exchange Commission (“SEC”) and was declared effective on July 21, 2020. A preliminary prospectus
supplement describing the terms of the offering was filed with the SEC on October 28, 2020, and is available on the SEC’s
website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus
relating to the offering may be obtained, when available, from H.C. Wainwright & Co., LLC, 430 Park Avenue 3rd Floor, New
York, NY 10022, or by calling (646) 975-6996 or by emailing placements@hcwco.com or at the SEC’s website at http://www.sec.gov.
This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the prospectus
supplement and accompanying prospectus forming a part of the effective registration statement.
About
Cancer Genetics, Inc.
Through
its vivoPharm subsidiary, Cancer Genetics offers proprietary preclinical test systems supporting drug discovery programs
valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The Company is focused on precision
and translational medicine to drive drug discovery toward novel and repurposed therapies. vivoPharm specializes in conducting
studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro
and in vivo data and reports, which are needed for Investigational New Drug filings. vivoPharm operates in the
Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited
facilities. For more information, please visit www.cancergenetics.com.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
All statements pertaining to Cancer Genetics, Inc.’s expectations regarding future financial and/or operating results, the
proposed offering of Cancer Genetics, Inc.’s shares of common stock, including as to the consummation of the public offering
described above and the use of net proceeds therefrom, potential for our tests and services and future revenues or growth in this
press release constitute forward-looking statements.
Any
statements that are not historical fact (including, but not limited to, statements that contain words such as “will,”
“believes,” “plans,” “anticipates,” “expects,” “estimates”) should
also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in our ability to satisfy all closing conditions to the merger with StemoniX, Inc., our attempts to
adapt to the global coronavirus pandemic, achieve profitability by increasing sales of our pre-clinical services, maintain our
existing customer base and avoid cancellation of customer contracts or discontinuance of trials, raise capital to meet our liquidity
needs, market and other conditions, properly evaluate strategic options, and other risks discussed in the Cancer Genetics, Inc.
Form 10-K for the year ended December 31, 2019 and Form 10-Q for the quarter ended June 30, 2020, along with other filings with
the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc.
disclaims any obligation to update these forward-looking statements.
Investor
Contacts:
Jennifer
K. Zimmons. Ph.D.
Investor Relations
Zimmons International Communications, Inc.
Email: jzimmons@zimmonsic.com
Phone: +1.917.214.3514
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2023 to Sep 2024